EP0466452A2 — Thioxo heterocycles and their pharmaceutical use
Assigned to AstraZeneca SAS · Expires 1992-01-15 · 34y expired
What this patent protects
The invention concerns a thioxo heterocycle of the formula I wherein Q is a 10-membered bicyclic heterocyclic moiety containing 1 or 2 N's which bears 1 or 2 thioxo substituents and which is optionally further substituted ; A 1 is a direct link to X 1 or (1-3C)alky…
USPTO Abstract
The invention concerns a thioxo heterocycle of the formula I wherein Q is a 10-membered bicyclic heterocyclic moiety containing 1 or 2 N's which bears 1 or 2 thioxo substituents and which is optionally further substituted ; A 1 is a direct link to X 1 or (1-3C)alkylene ; X 1 is oxy, thio, sulphinyl, sulphonyl or imino; Ar is optionally substituted phenylene or pyridylene ; R 1 is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkynyl; and R 2 and R 3 together form a group of the formula -A 2- X 2 -A 3- which, together with the carbon atom to which A 2 and A3 are attached, defines a ring having 5 to 7 ring atoms, wherein each of A 2 and A3 is (1-3C)alkylene and X 2 is oxy, thio, sulphinyl or sulphonyl ; or a pharmaceutically-acceptable salt thereof. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.
Drugs covered by this patent
- Pemazyre (PEMIGATINIB) · Incyte Corp
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.